Idinvest Partners

Onfido Named a Strong Performer in Inaugural Identity Verification Solutions Report by Independent Research Firm

Retrieved on: 
Monday, December 19, 2022

Onfido , the global identity verification provider, today announced it has been named a Strong Performer in The Forrester Wave™: Identity Verification Solutions, Q4 2022 , an inaugural report published by Forrester Research.

Key Points: 
  • Onfido , the global identity verification provider, today announced it has been named a Strong Performer in The Forrester Wave™: Identity Verification Solutions, Q4 2022 , an inaugural report published by Forrester Research.
  • “We are thrilled to be acknowledged as a strong performer in automated identity verification by Forrester Research,” said Mike Tuchen, CEO of Onfido.
  • Just this month, Onfido was recognized as a top leader in biometric authentication software and identity verification software for G2.com's Winter 2022 Report .
  • A comprehensive report containing findings from The Forrester Wave™: Identity Verification Solutions, Q4 2022 is available to view or download here .

Step Pharma to Present Promising Data on the Therapeutic Potential of Selective Small Molecule Inhibition of CTPS1 at the 64th American Society of Hematology Annual Meeting

Retrieved on: 
Thursday, November 3, 2022

Step Pharma and collaborators will present two posters on STP938, its potent and highly selective small molecule inhibitor of CTPS1, reporting its potential as a targeted therapeutic for the treatment of Mantle Cell Lymphoma and Multiple Myeloma.

Key Points: 
  • Step Pharma and collaborators will present two posters on STP938, its potent and highly selective small molecule inhibitor of CTPS1, reporting its potential as a targeted therapeutic for the treatment of Mantle Cell Lymphoma and Multiple Myeloma.
  • The Company is the world leader in CTPS1 inhibition, a new approach with the potential to yield highly selective, safe and effective cancer treatments for both blood cancers and solid tumours.
  • STP938 has the potential to be the backbone of a multitude of cancer therapies as well as a potent monotherapy for hard-to-treat blood cancers.
  • Step Pharma was founded in 2014 by Kurma Partners, the Imagine Institute and Sygnature Discovery, based on the scientific discoveries of Prof. Alain Fischer and Dr Sylvain Latour.

Step Pharma Announces First Patient Dosed with STP938, the World’s Most Advanced CTPS1 Inhibitor, in a Phase 1/2 Trial for T cell and B cell lymphomas

Retrieved on: 
Monday, October 24, 2022

The primary objective in Phase I is to assess the safety and tolerability of STP938.

Key Points: 
  • The primary objective in Phase I is to assess the safety and tolerability of STP938.
  • Brian Schwartz, Chief Medical Officer of Step Pharma, commented: We are developing STP938, a highly selective, first-in-class treatment based on ground-breaking genetics.
  • The dosing of the first patient into our Phase 1/2 trial is an important step to identify an optimal dose to take forward into further clinical development for relapsed/ refractory T cell and B cell lymphomas.
  • By targeting CTPS1, Step Pharma has unlocked the ability to selectively target the de novo pyrimidine synthesis pathway in cancer cells.

75% Of Businesses Are Willing to Accept Small Volumes of Fraud in Their Onboarding Process

Retrieved on: 
Tuesday, October 25, 2022

While executives cant control fraudsters or the regulatory environment, they do have control over their companys onboarding process.

Key Points: 
  • While executives cant control fraudsters or the regulatory environment, they do have control over their companys onboarding process.
  • More than 2 in 5 executives (41%) say it takes too long to review and verify each customer when onboarding.
  • Meet Onfido at Money20/20 October 24-26 at booth 1740 where well be showing businesses how they can simplify the onboarding and security process.
  • They partner with over 800 businesses globally to help millions access services every week from billion dollar institutions to hypergrowth start-ups.

Onfido Appoints Yuelin Li to Chief Product Officer

Retrieved on: 
Tuesday, October 18, 2022

Onfido , the leading global provider of automated identity verification and authentication solutions, today announced the promotion of Yuelin Li from Chief Strategy Officer to the role of Chief Product Officer.

Key Points: 
  • Onfido , the leading global provider of automated identity verification and authentication solutions, today announced the promotion of Yuelin Li from Chief Strategy Officer to the role of Chief Product Officer.
  • In her new role, Li will oversee the product strategy and direction of Onfidos Real Identity Platform, driving Onfido to further establish its category leadership in identity verification and fraud mitigation.
  • Yuelins promotion to Chief Product Officer is the result of her dedication to simplifying digital identity for our customers over the last five years and her expertise in developing a world-class product strategy and vision for Onfido, said Mike Tuchen, Chief Executive Officer at Onfido.
  • Im humbled to lead such a talented team of engineers and product leaders to build the next generation of market-leading identity solutions, said Yuelin Li, Chief Product Officer at Onfido.

Onfido named as a ‘Market Leader’ in KuppingerCole’s 2022 Market Compass: Providers of Verified Identity

Retrieved on: 
Monday, October 17, 2022

Onfido , the leading global provider of automated identity verification and authentication solutions, today announced that it has received the Market Leader distinction in the KuppingerCole Market Compass for Providers of Verified Identity 2022 , alongside Experian, IDEMIA, Microsoft and Ping Identity.

Key Points: 
  • Onfido , the leading global provider of automated identity verification and authentication solutions, today announced that it has received the Market Leader distinction in the KuppingerCole Market Compass for Providers of Verified Identity 2022 , alongside Experian, IDEMIA, Microsoft and Ping Identity.
  • KuppingerCole highlights several key Onfido strengths that influenced their review:
    The Leadership Compass Providers of Verified Identity 2022 analyzes digital identity solutions that perform identity proofing and verification or enable a verified digital identity to be imported and easily reverified.
  • The Leadership Compass compares full-service verified identity providers or vendors that conduct digital identity verification alongside providing several of the identity lifecycle stages.
  • Download the 2022 KuppingerCole Market Compass for Providers of Verified Identity.

MWM, Mobile App Development Studio, Announces the Launch of a Publishing Business Unit Focused on the US Market

Retrieved on: 
Monday, October 17, 2022

Mobile app publisher and development studio, MWM , today announced the launch of its new publishing business unit focused on the United States market with the ambition to become the leading publisher of non-gaming mobile apps.

Key Points: 
  • Mobile app publisher and development studio, MWM , today announced the launch of its new publishing business unit focused on the United States market with the ambition to become the leading publisher of non-gaming mobile apps.
  • Most app developers often lack the financial resources and technology stacks to acquire new users, monetize their products and deploy scalable and targeted advertising strategies.
  • At MWMs core is the vision to make creativity accessible to everyone without limitations, said Jean-Baptiste Hironde, CEO and Co-Founder of MWM.
  • That inspired my best friend and me to create Edjing Mix, which enables users to create mixes with smartphones or tablets.

Coave Therapeutics to Present at Cell and Gene Meeting on the Mesa

Retrieved on: 
Monday, September 26, 2022

The presentation will highlight how Coave is developing next generation gene therapy products based on its proprietary AAV-Ligand Conjugate ('ALIGATER') platform to transform gene therapy for neurodegenerative and eye diseases.

Key Points: 
  • The presentation will highlight how Coave is developing next generation gene therapy products based on its proprietary AAV-Ligand Conjugate ('ALIGATER') platform to transform gene therapy for neurodegenerative and eye diseases.
  • Coave's ligand conjugated AAV capsids (coAAVs) derived from the ALIGATER platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies.
  • Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.
  • Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.

Coave Therapeutics to Present at Cell and Gene Meeting on the Mesa

Retrieved on: 
Monday, September 26, 2022

The presentation will highlight how Coave is developing next generation gene therapy products based on its proprietary AAV-Ligand Conjugate ('ALIGATER') platform to transform gene therapy for neurodegenerative and eye diseases.

Key Points: 
  • The presentation will highlight how Coave is developing next generation gene therapy products based on its proprietary AAV-Ligand Conjugate ('ALIGATER') platform to transform gene therapy for neurodegenerative and eye diseases.
  • Coave's ligand conjugated AAV capsids (coAAVs) derived from the ALIGATER platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies.
  • Coave Therapeutics is a clinical-stage biotechnology company focused on developing life-changing gene therapies for CNS (Central Nervous System) and eye diseases.
  • Coave Therapeutics' next-generation AAV-Ligand Conjugate ('ALIGATER') platform enables targeted delivery and enhanced gene transduction to improve the effectiveness of advanced gene therapies for rare diseases.

Onfido Named an Identity Verification Leader on G2

Retrieved on: 
Monday, September 26, 2022

Onfido , the global provider of automated identity verification and authentication solutions, today announced G2.com users have ranked the company as a top leader in identity verification software for G2.com's Fall 2022 Report .

Key Points: 
  • Onfido , the global provider of automated identity verification and authentication solutions, today announced G2.com users have ranked the company as a top leader in identity verification software for G2.com's Fall 2022 Report .
  • In addition to its top ranking, Onfido has also been awarded the identity verification solution with the Highest User Adoption by G2.
  • We are honoured to be acknowledged as a leader in identity verification by G2, a trusted marketplace that ranks solutions directly from customers and users of our product and services, said Mike Tuchen, CEO of Onfido.
  • Recognized as a global leader in AI for identity verification and authentication, Onfido is backed by TPG Growth, Idinvest Partners, Crane Venture Partners, Salesforce Ventures, M12 (Microsoft) and others.